{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:55:11Z","timestamp":1791226511615,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.coph.2026.102674","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:02:28Z","timestamp":1789495348000},"page":"102674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cyclosporine A revisited: Molecular mechanisms, non-immune physiological pathways, and the architecture of multi-organ toxicities"],"prefix":"10.1016","volume":"91","author":[{"given":"Rasha Mokhtar","family":"Abdelkareem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa","family":"Obydah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-8572","authenticated-orcid":false,"given":"Ahmed M.","family":"Abd-Eldayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2026.102674_bib1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"key":"10.1016\/j.coph.2026.102674_bib2","first-page":"433","article-title":"History of the discovery of cyclosporin and of its early pharmacological development","volume":"114","author":"Borel","year":"2002","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.coph.2026.102674_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00000658-198209000-00012","article-title":"The use of cyclosporin A in clinical organ grafting","volume":"196","author":"Calne","year":"1982","journal-title":"Ann Surg"},{"key":"10.1016\/j.coph.2026.102674_bib4","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.transproceed.2004.01.042","article-title":"Cyclosporine as a milestone in immunosuppression","volume":"36","author":"Calne","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.coph.2026.102674_bib5","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","article-title":"Chemistry and toxicity - a review","volume":"28","author":"Patocka","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.coph.2026.102674_bib6","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1021\/acs.jmedchem.1c00580","article-title":"Cyclosporin structure and permeability: from A to Z and beyond","volume":"64","author":"Corbett","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2026.102674_sref7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63110-y","article-title":"Bio-synthesis, purification and structural analysis of Cyclosporine-A produced by Tolypocladium inflatum with valorization of agro-industrial wastes","volume":"14","author":"Falah","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2026.102674_bib8","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.bbagen.2014.12.009","article-title":"Biosynthesis of cyclosporins and other natural peptidyl prolyl cis\/trans isomerase inhibitors","volume":"1850","author":"Lawen","year":"2015","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.coph.2026.102674_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3108749","article-title":"Development of a population pharmacokinetic model for cyclosporine from therapeutic drug monitoring data","volume":"2021","author":"Umpi\u00e9rrez","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.coph.2026.102674_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106882","article-title":"Population pharmacokinetics of cyclosporine A in hematopoietic stem cell transplant recipients: a systematic review","volume":"204","author":"Yang","year":"2025","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.coph.2026.102674_bib11","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/j.1600-6143.2006.01518.x","article-title":"CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study","volume":"6","author":"Haufroid","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coph.2026.102674_sref12","first-page":"99","article-title":"Population pharmacokinetics model of cyclosporin A in children and young adult renal transplant patients: focus on haemoglobin contribution to exposure variability","volume":"18","author":"Roganovi\u0107","year":"2026","journal-title":"Pharm Times"},{"key":"10.1016\/j.coph.2026.102674_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/bdd.1967","article-title":"Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data","author":"Srinivas","year":"2015","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.coph.2026.102674_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2217\/pgs-2017-0127","article-title":"Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients","volume":"18","author":"Sun","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.coph.2026.102674_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00228-012-1355-x","article-title":"ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients","volume":"69","author":"Garc\u00eda","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_sref16","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/ijms26051960","article-title":"Trends in precision medicine and pharmacogenetics as an adjuvant in establishing a correct immunosuppressive therapy for kidney transplant: an up-to-date historical overview","volume":"26","author":"Belardi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102674_bib17","first-page":"167","article-title":"Intelligent Pharmacy\u2019s applications of cyclosporine","volume":"1","author":"Zhang","year":"2023","journal-title":"Int Pharmacop"},{"key":"10.1016\/j.coph.2026.102674_bib18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11096-023-01545-5","article-title":"Developing supervised machine learning algorithms to evaluate the therapeutic effect and laboratory-related adverse events of cyclosporine and tacrolimus in renal transplants","volume":"45","author":"Sridharan","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.coph.2026.102674_sref19","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2026.1763546","article-title":"Kidney-targeted drug delivery: from physiological mechanisms to precision therapeutics","volume":"14","author":"Tan","year":"2026","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.coph.2026.102674_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejogrb.2023.12.039","article-title":"Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy: a narrative review with emphasis on efficacy and safety","volume":"294","author":"Jiang","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.coph.2026.102674_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/gb-2005-6-7-226","article-title":"The cyclophilins","volume":"6","author":"Wang","year":"2005","journal-title":"Genome Biol"},{"key":"10.1016\/j.coph.2026.102674_bib22","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"<p>A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation Developments<\/p>","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.coph.2026.102674_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/16078454.2022.2081008","article-title":"The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials","volume":"27","author":"tian","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.coph.2026.102674_bib24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s13346-019-00650-1","article-title":"Recent advances in cyclosporine drug delivery: challenges and opportunities","volume":"9","author":"Patel","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.coph.2026.102674_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fimmu.2020.00195","article-title":"The role of Calcium\u2013Calcineurin\u2013NFAT signaling pathway in health and autoimmune diseases","volume":"11","author":"Park","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102674_bib26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bcp.2019.03.022","article-title":"Modulation of innate immunity by cyclosporine A","volume":"163","author":"Liddicoat","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib27","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3390\/cells8091052","article-title":"Cyclosporin A increases mitochondrial buffering of calcium: an additional mechanism in delaying mitochondrial permeability transition pore opening","volume":"8","author":"Mishra","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.coph.2026.102674_bib28","doi-asserted-by":"crossref","first-page":"411.e1","DOI":"10.1016\/j.jtct.2022.04.010","article-title":"Cyclosporine A regulates PMN-MDSCs viability and function through MPTP in acute GVHD: old medication, new target","volume":"28","author":"Li","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coph.2026.102674_bib29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jtcvs.2007.09.075","article-title":"Dual immunosuppression enhances vasomotor injury: interactive effect between endothelin-1 and nitric oxide bioavailability","volume":"135","author":"Ramzy","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.coph.2026.102674_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000539700","article-title":"Protects podocytes by regulating transgelin in Adriamycin-Induced podocyte injury","volume":"49","author":"Li","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.coph.2026.102674_sref31","doi-asserted-by":"crossref","DOI":"10.1111\/apha.70047","article-title":"Calcineurin inhibitor associated nephrotoxicity in kidney Transplantation\u2014A transplant Nephrologist\u2019s perspective","volume":"241","author":"Hansen","year":"2025","journal-title":"Acta Physiol"},{"key":"10.1016\/j.coph.2026.102674_sref32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/antiox15040412","article-title":"Oxidative stress-driven mechanisms and biomarkers of drug-induced nephrotoxicity: translational insights and therapeutic implications","volume":"15","author":"Ahamad","year":"2026","journal-title":"Antioxidants"},{"key":"10.1016\/j.coph.2026.102674_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.toxlet.2024.03.009","article-title":"Cyclosporine A-induced systemic metabolic perturbations in rats: a comprehensive metabolome analysis","volume":"395","author":"Yen","year":"2024","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.coph.2026.102674_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116799","article-title":"Endoplasmic reticulum stress and unfolded protein response: roles in skeletal muscle atrophy","volume":"234","author":"Ji","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/ph19071056","article-title":"The central role of the AMPK\/SIRT1\/PGC-1\u03b1 signaling axis in skeletal muscle physiology and pathology and its targeted therapeutic strategies","volume":"19","author":"Wang","year":"2026","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coph.2026.102674_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70657","article-title":"AMPK\/SIRT1\/PGC-1\u03b1 signaling pathway: molecular mechanisms and targeted strategies from energy homeostasis regulation to disease therapy","volume":"31","author":"Chen","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.coph.2026.102674_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-025-10862-z","article-title":"The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients","volume":"52","author":"Bouafia","year":"2025","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.coph.2026.102674_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-811X-12-8","article-title":"Calcineurin\/NFAT signaling and innate host defence: a role for NOD1-mediated phagocytic functions","volume":"12","author":"Vandewalle","year":"2014","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.coph.2026.102674_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2021.102163","article-title":"Evaluating the effects of Cyclosporine A immunosuppression on mycobacterial infection by inhaling of Cyclosporine A administrated BALB\/c mice with live Bacillus Calmette Gu\u00e9rin","volume":"132","author":"Motiee","year":"2022","journal-title":"Tuberculosis"},{"key":"10.1016\/j.coph.2026.102674_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.14740\/jocmr2104w","article-title":"Fungal infections in renal transplant patients","volume":"7","author":"Khan","year":"2015","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.coph.2026.102674_bib41","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.ajt.2025.07.2480","article-title":"Invasive Candida infections in solid organ transplant recipients between 2008 and 2020","volume":"25","author":"Meyer","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coph.2026.102674_bib42","article-title":"Carcinogenic medications: a review of specific agents and molecular mechanisms of carcinogenesis","volume":"9","author":"Seyoum Tadesse","year":"2026","journal-title":"Cancer Rep"},{"key":"10.1016\/j.coph.2026.102674_bib43","first-page":"198","article-title":"Cancer immunotherapy: role of the immune system in malignant transformation","volume":"82","author":"Sandoval-Valencia","year":"2019","journal-title":"Rev m\u00e9dica del Hosp Gen M\u00e9xico"},{"key":"10.1016\/j.coph.2026.102674_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1146002","article-title":"Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation","volume":"13","author":"Shaw","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.coph.2026.102674_bib45","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1038\/s41598-024-57300-x","article-title":"Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-\u03b1, NF-\u03baB, and Bax","volume":"14","author":"Abd-Eldayem","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2026.102674_bib46","first-page":"2441","article-title":"Clinical nephrotoxicity induced by cyclosporin A combined with hormone therapy for nephrotic syndrome","volume":"34","author":"Liu","year":"2021","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.coph.2026.102674_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103660","article-title":"Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model","volume":"9","author":"Carlos","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2026.102674_sref48","doi-asserted-by":"crossref","DOI":"10.1111\/apha.14190","article-title":"Immunosuppression with cyclosporine versus tacrolimus shows distinctive nephrotoxicity profiles within renal compartments","volume":"240","author":"Demirci","year":"2024","journal-title":"Acta Physiol"},{"key":"10.1016\/j.coph.2026.102674_bib49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11255-016-1439-0","article-title":"Klotho mitigates cyclosporine A (CsA)-induced epithelial-mesenchymal transition (EMT) and renal fibrosis in rats","volume":"49","author":"Liu","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.coph.2026.102674_sref50","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/s12967-026-08252-5","article-title":"Cyclosporine A promotes renal fibrosis through activating endoplasmic reticulum stress by targeting miR-212-5p\/ATF6 axis","volume":"24","author":"Wang","year":"2026","journal-title":"J Transl Med"},{"key":"10.1016\/j.coph.2026.102674_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.intimp.2017.08.019","article-title":"Attenuation of cyclosporine A induced nephrotoxicity by schisandrin B through suppression of oxidative stress, apoptosis and autophagy","volume":"52","author":"Lai","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib52","article-title":"The dual pathological roles and targeted therapy of PGE2: from receptor signaling networks to disease microenvironment modulation","volume":"17","author":"Yang","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1844637","article-title":"The cGAS\u2013STING pathway in tumor immunity: dual roles, regulatory mechanisms, and precision therapeutic strategies","volume":"17","author":"Jiang","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib54","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.fct.2018.06.054","article-title":"Mechanism of cyclosporine A nephrotoxicity: oxidative stress, autophagy, and signalings","volume":"118","author":"Wu","year":"2018","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.coph.2026.102674_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/japtr.JAPTR_336_18","article-title":"Nephrotoxicity: role and significance of renal biomarkers in the early detection of acute renal injury","volume":"10","author":"Al-Naimi","year":"2019","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.coph.2026.102674_bib56","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/biology10050442","article-title":"Camel milk mitigates cyclosporine-induced renal damage in rats: targeting p38\/erk\/jnk mapks, nf-\u03bab, and matrix metalloproteinases","volume":"10","author":"Arab","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.coph.2026.102674_sref57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1756582","article-title":"Vericiguat attenuates cyclosporine A-induced nephropathy by targeting the NF-\u03baB\/TGF-\u03b21 axis: an integrated network pharmacology, Mendelian randomization, and experimental study","volume":"16","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102674_bib58","first-page":"57","article-title":"Mechanisms of cyclosporin A induced hepatotoxicity","volume":"6","author":"Faheem","year":"2022","journal-title":"Rec Pharm Biomed Sci"},{"key":"10.1016\/j.coph.2026.102674_bib59","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3390\/foods15091473","article-title":"Hepato-protective effect of pomegranate and persimmon juices against oxidative stress and inflammation in cyclosporine-induced cholestasis in rats","volume":"15","author":"Mohamed","year":"2026","journal-title":"Foods"},{"key":"10.1016\/j.coph.2026.102674_bib60","first-page":"343","article-title":"Hepatoprotective and antioxidant potential of Calotropis gigantea in Cyclosporine\u2013An induced hepatotoxicity","volume":"2","author":"Kshirsagar","year":"2010","journal-title":"Res J Pharmacol Pharmacodyn"},{"key":"10.1016\/j.coph.2026.102674_bib61","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jss.2014.08.042","article-title":"Effects of antioxidant agents against cyclosporine-induced hepatotoxicity","volume":"193","author":"Akbulut","year":"2015","journal-title":"J Surg Res"},{"key":"10.1016\/j.coph.2026.102674_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1004844","article-title":"Involvement of oxidative species in cyclosporine-mediated cholestasis","volume":"13","author":"Nsengimana","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib63","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.transproceed.2004.09.011","article-title":"Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole","volume":"37","author":"Videla","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.coph.2026.102674_bib64","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/BF01296488","article-title":"Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man","volume":"37","author":"Cadranel","year":"1992","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2026.102674_bib65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF01540169","article-title":"Liver injury from cyclosporine A","volume":"35","author":"Kassianides","year":"1990","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2026.102674_bib66","article-title":"Frequency and risk factors of cyclosporine-induced neurotoxicity in allogeneic stem cell transplant recipients","volume":"13","author":"Danish","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2026.102674_sref67","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/aian.aian_614_24","article-title":"Neurotoxicity of calcineurin inhibitors","volume":"28","author":"Bajon","year":"2025","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.coph.2026.102674_bib68","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/HYPERTENSIONAHA.117.10306","article-title":"Myeloid-derived suppressor cells ameliorate cyclosporine A-Induced hypertension in mice","volume":"71","author":"Chiasson","year":"2018","journal-title":"Hypertension (Dallas)"},{"key":"10.1016\/j.coph.2026.102674_sref69","doi-asserted-by":"crossref","DOI":"10.1111\/apha.14199","article-title":"Cardiovascular toxicities by calcineurin inhibitors: cellular mechanisms behind clinical manifestations","volume":"240","author":"Attachaipanich","year":"2024","journal-title":"Acta Physiol"},{"key":"10.1016\/j.coph.2026.102674_bib70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jat.4203","article-title":"Potential role of circular RNA in cyclosporin A-induced cardiotoxicity in rats","volume":"42","author":"Zhao","year":"2022","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.coph.2026.102674_bib71","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3390\/jcm11144080","article-title":"Dyslipidemia in transplant patients: which therapy?","volume":"11","author":"Iannuzzo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.coph.2026.102674_bib72","article-title":"Cyclosporin A-Induced dyslipidemia and LDL receptors","author":"Kockx","year":"2019","journal-title":"Mol Nutr Fats"},{"key":"10.1016\/j.coph.2026.102674_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.117999","article-title":"Network of cell death in myocardial ischemia-reperfusion injury: mechanisms and targeted therapeutic strategies","volume":"250","author":"Qi","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib74","article-title":"Periodontal management of cyclosporin A-Induced gingival overgrowth: a nonsurgical approach","volume":"2019","author":"Malek","year":"2019","journal-title":"Case Rep Dent"},{"key":"10.1016\/j.coph.2026.102674_bib75","article-title":"Cyclosporine-induced gingival hyperplasia in a patient with lichen planopilaris: misfortunes never come singly","volume":"15","author":"Zisis","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2026.102674_bib76","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.abd.2019.08.027","article-title":"Cyclosporine-induced childhood generalized hypertrichosis","volume":"95","author":"Souza","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.coph.2026.102674_bib77","doi-asserted-by":"crossref","first-page":"117913","DOI":"10.1016\/j.bcp.2026.117913","article-title":"Molecular mechanisms of skeletal muscle atrophy: clinical challenges and future therapeutic strategies","volume":"249","author":"Gong","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib78","first-page":"77","article-title":"Muscular dystrophy muscle preservation: a comparative systematic review of exercise and cannabidiol (CBD) interventions","volume":"9","author":"Aabedi","year":"2026","journal-title":"J Biotechnol Biomed"},{"key":"10.1016\/j.coph.2026.102674_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.118219","article-title":"The role of Piezo1 in skeletal muscle physiology and pathology: from mechanosensing to precision therapy","volume":"252","author":"Xue","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1264496","article-title":"Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models","volume":"14","author":"Abboud","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102674_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1795626","article-title":"Comparative neuropsychiatric safety signals of tacrolimus versus cyclosporine in solid organ transplantation: ten-year FAERS pharmacovigilance study","volume":"17","author":"Almalki","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102674_bib82","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaad.2023.05.074","article-title":"Systemic calcineurin inhibitors tacrolimus and voclosporin: a review of off-label dermatologic uses","volume":"90","author":"Dai","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2026.102674_bib83","doi-asserted-by":"crossref","DOI":"10.1155\/ijcp\/1982331","article-title":"Efficacy and safety of cyclosporine and tacrolimus in rheumatoid arthritis: a systematic review and meta-analysis","volume":"2026","author":"Kim","year":"2026","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.coph.2026.102674_bib84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2174\/0125899775258634231226052204","article-title":"The journey of methotrexate and potential alternative pharmacotherapies for rheumatoid arthritis","volume":"17","author":"Patra","year":"2024","journal-title":"Curr Drug Res Rev"},{"key":"10.1016\/j.coph.2026.102674_bib85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12016-016-8582-3","article-title":"The use of cyclosporine A in rheumatology: a 2016 comprehensive review","volume":"52","author":"Chighizola","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coph.2026.102674_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2025.1525868","article-title":"The evolving role of ciclosporin in the management of vernal keratoconjunctivitis","volume":"5","author":"Kanda","year":"2025","journal-title":"Front Ophthalmol"},{"key":"10.1016\/j.coph.2026.102674_bib87","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/life14030361","article-title":"Immunopathological insights and therapeutic applications of immunomodulators","volume":"14","author":"Hehar","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.coph.2026.102674_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70463","article-title":"Cyclosporine use in paediatric dermatologic conditions: a comprehensive review of therapeutic applications","author":"Del Pozzo-Magana","year":"2026","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.coph.2026.102674_bib89","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ard.2026.02.009","article-title":"EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome: 2025 update","volume":"85","author":"Hatemi","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2026.102674_bib90","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13555-020-00370-2","article-title":"Cyclosporine with and without systemic corticosteroids in treatment of alopecia areata: a systematic review","volume":"10","author":"Nowaczyk","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coph.2026.102674_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00588","article-title":"Lessons to learn from low-dose cyclosporin-A: a new approach for unexpected clinical applications","volume":"10","author":"Flores","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102674_bib92","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/CCM.0b013e318283caef","article-title":"Cyclosporine A cardioprotection: mechanisms and potential for clinical application","volume":"41","author":"B\u00fcnger","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.coph.2026.102674_bib93","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1476-5381.2011.01700.x","article-title":"Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent","volume":"165","author":"Hausenloy","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib94","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/SHK.0000000000000357","article-title":"Evaluation of cyclosporine a as a Cardio- and neuroprotective agent after cardiopulmonary resuscitation in a rat model","volume":"43","author":"Knapp","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.coph.2026.102674_bib95","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJMoa071142","article-title":"Effect of cyclosporine on reperfusion injury in acute myocardial infarction","volume":"359","author":"Piot","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2026.102674_bib96","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2015.11.024","article-title":"Cyclosporine A Prior to Primary PCI in STEMI Patients: the Coup de Gr\u00e2ce to Post-Conditioning?","volume":"67","author":"Chen-Scarabelli","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2026.102674_bib97","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2009.10.052","article-title":"Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction","volume":"55","author":"Mewton","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2026.102674_bib98","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ahj.2015.02.020","article-title":"Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial)","volume":"169","author":"Mewton","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.coph.2026.102674_bib99","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa1505489","article-title":"Cyclosporine before PCI in patients with acute myocardial infarction","volume":"373","author":"Cung","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2026.102674_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12010","article-title":"The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction","volume":"31","author":"Ghaffari","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.coph.2026.102674_bib101","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jacc.2015.10.081","article-title":"Cyclosporine A in reperfused myocardial infarction the multicenter, controlled, open-label CYCLE trial","volume":"67","author":"Ottani","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2026.102674_bib102","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fphar.2018.00238","article-title":"Efficacy and safety of cyclosporine in acute myocardial infarction: a systematic review and meta-analysis","volume":"9","author":"Rahman","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102674_bib103","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.npep.2011.04.002","article-title":"Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application","volume":"45","author":"Osman","year":"2011","journal-title":"Neuropeptides"},{"key":"10.1016\/j.coph.2026.102674_bib104","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s13311-023-01414-z","article-title":"Cyclosporine as therapy for traumatic brain injury","volume":"20","author":"Hansson","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.coph.2026.102674_bib105","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1089\/neu.2018.6369","article-title":"Copenhagen head injury Ciclosporin study: a phase IIa safety, pharmacokinetics, and biomarker study of Ciclosporin in severe traumatic brain injury patients","volume":"36","author":"Kelsen","year":"2019","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.coph.2026.102674_bib106","first-page":"2547","article-title":"Short-term cyclosporin A treatment reduced serum neurofilament-light levels in diffuse but not focal traumatic brain injury in a piglet model","volume":"13","author":"Huber","year":"2025","journal-title":"Biomed"},{"key":"10.1016\/j.coph.2026.102674_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00151","article-title":"Effect of cyclosporine on lesion growth and infarct size within the white and gray matter","volume":"8","author":"Ong","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.coph.2026.102674_bib108","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1212\/WNL.0000000000001639","article-title":"Cyclosporine in acute ischemic stroke","volume":"84","author":"Nighoghossian","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2026.102674_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106673","article-title":"Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2","volume":"193","author":"Guareschi","year":"2024","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.coph.2026.102674_sref110","article-title":"Comparing the efficacy of nanocarriers for cutaneous and follicular delivery of poorly water-soluble molecules: a case study with ciclosporin A","volume":"11","author":"Darade","year":"2026","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.coph.2026.102674_bib111","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamadermatol.2016.0859","article-title":"Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial","volume":"152","author":"Kumar","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2026.102674_bib112","doi-asserted-by":"crossref","first-page":"41565","DOI":"10.1021\/acsomega.4c05346","article-title":"Ionic liquid-mediated transdermal delivery of organogel containing cyclosporine A for the effective treatment of psoriasis","volume":"9","author":"Datta","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.coph.2026.102674_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106994","article-title":"Therapeutic effect of cyclosporine A-loading TPGS micelles on a mouse model of LPS-induced neuroinflammation","volume":"205","author":"Guareschi","year":"2025","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.coph.2026.102674_bib114","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s13346-025-02014-4","article-title":"A liposomal formulation of cyclosporine a shows promising results in treating symptoms of moderate to severe dry eye disease in dogs","volume":"16","author":"Caballo-Gonz\u00e1lez","year":"2026","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.coph.2026.102674_bib115","first-page":"1682","article-title":"Long-term efficacy and safety of 0.1% cyclosporine A cationic emulsion in advanced dry eye disease: a 24-Month retrospective study","volume":"18","author":"Sarnat-Kucharczyk","year":"2025","journal-title":"Pharm Times"},{"key":"10.1016\/j.coph.2026.102674_bib116","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40005-024-00720-8","article-title":"Enhanced therapeutic efficacy of cyclosporin A eluting hyaluronic acid contact lenses in the management of dry eye disease","volume":"55","author":"Mondal","year":"2025","journal-title":"J Pharm Investig"},{"key":"10.1016\/j.coph.2026.102674_bib117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/247553031420a00301","article-title":"Safety and efficacy of cyclosporine in psoriatic arthritis","volume":"20a","author":"Alessa","year":"2014","journal-title":"Psoriasis Forum"},{"key":"10.1016\/j.coph.2026.102674_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"PLoS One"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:44:45Z","timestamp":1791225885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489226000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":118,"alternative-id":["S1471489226000706"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2026.102674","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporine A revisited: Molecular mechanisms, non-immune physiological pathways, and the architecture of multi-organ toxicities","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2026.102674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102674"}}